Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases
| العنوان: | Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases |
|---|---|
| المؤلفون: | Juan Decara, Patricia Rivera, Antonio Jesús López-Gambero, Antonia Serrano, Francisco Javier Pavón, Elena Baixeras, Fernando Rodríguez de Fonseca, Juan Suárez |
| المصدر: | Frontiers in Pharmacology Frontiers in Pharmacology, Vol 11 (2020) |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, PPARγ, medicine.medical_treatment, Peroxisome proliferator-activated receptor, Inflammation, Review, PPARα, inflammatory bowel diseases, Proinflammatory cytokine, 03 medical and health sciences, 0302 clinical medicine, PPARβ/δ, medicine, Pharmacology (medical), Receptor, ulcerative colitis, chemistry.chemical_classification, Pharmacology, business.industry, lcsh:RM1-950, Lipid metabolism, Crohn's disease, lcsh:Therapeutics. Pharmacology, 030104 developmental biology, Cytokine, chemistry, Nuclear receptor, 030220 oncology & carcinogenesis, Cancer research, Tumor necrosis factor alpha, medicine.symptom, business |
| الوصف: | The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that promote ligand-dependent transcription of target genes that regulate energy production, lipid metabolism, and inflammation. The PPAR superfamily comprises three subtypes, PPARα, PPARγ, and PPARβ/δ, with differential tissue distributions. In addition to their different roles in the regulation of energy balance and carbohydrate and lipid metabolism, an emerging function of PPARs includes normal homeostasis of intestinal tissue. PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, while PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Il-1β. In this regard, the anti-inflammatory responses induced by PPAR activation might restore physiopathological imbalances associated with inflammatory bowel diseases (IBD). Thus, PPARs and their ligands have important therapeutic potential. This review briefly discusses the roles of PPARs in the physiopathology and therapies of the most important IBDs, ulcerative colitis (UC), and Crohn's disease (CD), as well some new experimental compounds with PPAR activity as promising drugs for IBD treatment. |
| وصف الملف: | application/pdf |
| تدمد: | 1663-9812 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfde52bb0f113ea542c453e83e381d7 https://pubmed.ncbi.nlm.nih.gov/32536865 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....5bfde52bb0f113ea542c453e83e381d7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16639812 |
|---|